Filter by content type
Filter by year
Vaccinex Reports Third Quarter 2019 Financial Results and Provides Corporate Update
November 12, 2019 - … enrollment of the dose expansion cohort in the Phase 1b/2 CLASSICAL-Lung study in non-small cell lung cancer; primary completion … expected by the end of 2019 Updated interim data from the CLASSICAL-Lung study at the Society for Immunotherapy of …
Vaccinex Reports Second Quarter 2019 Financial Results and Provides Corporate Update
August 14, 2019 - … enrollment of the dose expansion cohort in the Phase 1b/2 CLASSICAL-Lung study in non-small cell lung cancer; primary completion … in the second half of 2019 Presented interim data from CLASSICAL-Lung study at the 2019 American Society of Clinical …
Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
November 9, 2019 - … Combination with Avelumab (BAVENCIO(R)) in Non-Small Cell Lung Cancer at the 34th Annual Meeting of the Society for … from the poster presentation. Updated Interim Data The CLASSICAL-Lung trial is being conducted in collaboration with … of the Company's website, www.vaccinex.com . About the CLASSICAL - Lung Clinical Trial The design of the trial …
Vaccinex Announces Award Notice from the Alzheimer’s Association 2020 Part the Cloud Program
November 14, 2019 - … with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington's disease. Vaccinex is based in … our plans, expectations and objectives with respect to the CLASSICAL-Lung clinical trial, the combination of pepinemab … our plans, expectations and objectives with respect to the CLASSICAL-Lung clinical trial, the combination of pepinemab …
Vaccinex Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 15, 2019 - … Update 05/15/19 Earnings Updated interim data from CLASSICAL-Lung study to be presented at the annual meeting of the … results from the dose escalation phase of the ongoing CLASSICAL-Lung Phase 1b/2 study at the American Association …
Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer in Podium and Poster Presentations at the Fifth International Cancer lmmunotherapy Conference in Paris, France
September 27, 2019 - … Combination with Avelumab (BAVENCIO(R)) in Non-Small Cell Lung Cancer in Podium and Poster Presentations at the Fifth … for Cancer Research (AACR). Updated Interim Data The CLASSICAL-Lung trial is being conducted in collaboration with … our plans, expectations and objectives with respect to the CLASSICAL-Lung clinical trial, the combination of pepinemab …
Vaccinex Announces Full Enrollment Achieved in Ongoing CLASSICAL-Lung Phase 1b/2 Trial of Pepinemab in Combination with BAVENCIO® (avelumab) in Advanced Non-Small Cell Lung Cancer
August 13, 2019 - … Vaccinex Announces Full Enrollment Achieved in Ongoing CLASSICAL-Lung Phase 1b/2 Trial of Pepinemab in Combination with … … Vaccinex Announces Full Enrollment Achieved in Ongoing CLASSICAL-Lung Phase 1b/2 Trial of Pepinemab in Combination …
Vaccinex, Inc. Summary of Key Data Presented at the 2019 Annual Meeting of the American Association for Cancer Research (AACR)
April 9, 2019 - … Research (AACR) 04/09/19 General First Interim Results of CLASSICAL-Lung Phase 1b/2 Study Demonstrate Up To 90 Percent Disease … The company presented interim data for its Phase 1b/2 CLASSICAL-Lung study of its pepinemab antibody in combination …
Vaccinex Presents Updated Interim Results from a Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Non-Small Cell Lung Cancer at the 2019 ASCO Annual Meeting
June 3, 2019 - … Pepinemab in Combination with Avelumab in Non-Small Cell Lung Cancer at the 2019 ASCO Annual Meeting … Vaccinex … of the presentation, presented "Interim results from CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) … the many subject volunteers and clinicians involved in the CLASSICAL-Lung clinical trial with whom we share a hope for …
Vaccinex Announces $3 Million Award from the Alzheimer’s Drug Discovery Foundation
December 10, 2019 - … and our collaboration with Merck KGaA in Non-Small Cell Lung Cancer could bring important benefits to our patients … with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington's disease. Vaccinex is based in … and our collaboration with Merck KGaA in Non-Small Cell Lung Cancer could bring important benefits to our patients …